New Audio Updates: CCO Independent Conference Coverage of Hepatitis B at AASLD 2023

CCO Infectious Disease Podcast

English - February 05, 2024 14:59 - 37 minutes - 34.2 MB
Courses Education Science Life Sciences hiv covid-19 cme hepatitis b hbv id medical education coronavirus hepatitis c hcv Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Reconsidering Your Approach: Strategies to Support PrEP Persistence and Reengagement

Next Episode: COVID-19 Case Challenges: Employing Outpatient Antivirals and Addressing Drug‒Drug Interactions

In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:

Current therapiesStudies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDFKaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis BEarly vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV TransmissionInvestigational functional cure strategiesB-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV InfectionMARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV InfectionREEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHBHBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV InfectionCVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV Infection

Presenter:
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois

Link to full program:
https://bit.ly/47XJlU4